Skip to main content
Premium Trial:

Request an Annual Quote

Oncocyte Realigns Operations, Implements Cost Reduction Programs

NEW YORK – Oncocyte said after the close of the market on Wednesday that it is realigning its operations and implementing cost reduction programs to prioritize near-term revenue generators and better manage and preserve its cash.

The strategy includes reducing its workforce, which is expected to decrease the firm's operating costs by more than $4.5 million annually. Layoffs started on Aug. 8 and are set to be completed by Sept. 30, the Irvine, California-based company said in a Form 8-K filed with the US Securities and Exchange Commission.

It added in a press release that through reprioritization efforts and strategic activities, along with the headcount reduction, operating costs are expected to be trimmed by about $12 million in 2023 compared to 2022.

Oncocyte also said on Wednesday that its second quarter revenues rose 5 percent to $2.1 million from $2 million a year ago, falling short of the consensus Wall Street estimate of $2.7 million.

It noted that it received a $1 million milestone payment during Q2 from the final delivery of the DetermaRx lung cancer test to its Chinese partner Burning Rock.

The company had a net loss of $8.3 million, or $.07 per share, for the three months ended June 30 compared to a net loss of $10.5 million, or $.12 per share, a year ago. Its R&D costs more than doubled year over year to $5.6 million from $2.5 million, while its SG&A costs retreated 15 percent to $9.0 million from $10.6 million.

The firm ended Q2 with $44.8 million in cash and cash equivalents, $1.7 million in restricted cash, and $579,000 in marketable equitable securities. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.